FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W768123309> ?p ?o ?g. }

• W768123309 abstract "Abstract Abstract 786 Acute Myeloid Leukemia (AML) results from a combination of oncogenic events that can involve multiple signal transduction pathways including mutation-induced activation of tyrosine kinases. Kinase inhibitors are increasingly studied as promising targeted approaches either alone or in combination with other agents. However, only subsets of patients respond to respective targeted therapies. We hypothesize that the phosphorylation status of certain sets of proteins (phosphosignatures) can predict the clinical response. In recent years, advances in sample processing, mass spectrometry, and computer algorithms for the analyses of proteomics data have enabled the application of mass spectrometry-based proteomics to monitor phosphorylation events in a global and unbiased manner. These methods have become sufficiently sensitive and robust to identify and quantify thousands of phosphorylation sites in a single experiment. Furthermore, spiking-in a SILAC- (stable-isotope labelling by amino acids in cell culture) reference sample (Super-SILAC) allows for the precise quantification of phosphorylation events also in in-vivo samples. Internal tandem duplication (ITD) of FLT3 is one of the most common mutations in AML. It causes constitutive activation of FLT3. AC220 (Quizartinib®, Ambit) is a selective inhibitor of the receptor-type tyrosine-protein kinase FLT3 that is currently under development for the treatment of AML. In a recent phase II open-label study, patients with relapsed AML were treated with AC220. The results of this trial will be reported elsewhere. Here, we sought to identify phosphorylation events that predict clinical response with high accuracy, especially in the group of FLT3-ITD-positive patients. To this end, we established a global, quantitative phosphoproteome analysis of AML cells derived from patient bone marrow. We analyzed samples from 15 patients before treatment with AC220 and employed the obtained phosphoproteomics data to discover a predictive signature of phosphorylation markers. In total, we confidently identified and quantified roughly 10,000 phosphorylation sites. Unsupervised clustering of the data revealed two large clusters that are both characterized by stronger phosphorylation of associated protein kinases. Next, we correlated these clusters with the reported clinical response of the respective patients. Although the clustering was unsupervised regarding the response information, the two clusters almost perfectly separated responders (complete or partial remission) from non-responders (stable or progressive disease). Furthermore, we identified a signature comprising four phosphorylation sites that accurately predict the outcome of therapy based on the corresponding phosphorylations obtained before treatment. We evaluated the performance of this signature in a cross-validation set-up and in additional test samples that have not been used for training. Moreover, we validated the robustness of the selected predictive features. Our study supports that the phosphorylation of four proteins are candidate biomarkers for predicting response to AC220 in AML. Notably, the phosphorylation markers are more predictive than the FTL3-ITD status alone and will thus allow a more precise stratification of AML patients for treatment with AC220. In addition, our results demonstrate for the first time that identifying predictive phosphorylation signatures directly from clinical patient samples is possible. Disclosures: Schaab: Kinaxo, Evotec: Employment, Research Funding. Oppermann:Kinaxo, Evotec: Employment, Research Funding. Pfeifer:Ambit: Joined performance of clinical trial, Joined performance of clinical trial Other; Kinaxo, Evotec: Research Funding. Klammer:Kinaxo, Evotec: Employment, Research Funding. Tebbe:Kinaxo, Evotec: Employment, Research Funding. Oellerich:Kinaxo, Evotec: Research Funding; Ambit: Joined performance of clinical trial, Joined performance of clinical trial Other. Krauter:Ambit: Joined performance of clinical trial Other. Levis:Astellas Pharma: Consultancy; Plexxikon: Consultancy; Symphogen: Consultancy; Ambit: Joined performance of clinical trial, Joined performance of clinical trial Other. Perl:Ambit: Joined performance of clinical trial Other. Daub:Kinaxo, Evotec: Employment, Research Funding. Steffen:Kinaxo, Evotec: Research Funding; Ambit: Joined performance of clinical trial, Joined performance of clinical trial Other. Godl:Kinaxo, Evotec: Employment, Research Funding. Serve:Ambit: Joined performance of clinical trial, Joined performance of clinical trial Other; Kinaxo, Evotec: Research Funding." @default.
• W768123309 created "2016-06-24" @default.
• W768123309 creator A5006407427 @default.
• W768123309 creator A5015273169 @default.
• W768123309 creator A5020375942 @default.
• W768123309 creator A5023951641 @default.
• W768123309 creator A5025165056 @default.
• W768123309 creator A5037460404 @default.
• W768123309 creator A5053972254 @default.
• W768123309 creator A5077872272 @default.
• W768123309 creator A5078221812 @default.
• W768123309 creator A5086016311 @default.
• W768123309 creator A5086644018 @default.
• W768123309 creator A5089694123 @default.
• W768123309 creator A5091612811 @default.
• W768123309 date "2012-11-16" @default.
• W768123309 modified "2023-09-27" @default.
• W768123309 title "Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220" @default.
• W768123309 doi "https://doi.org/10.1182/blood.v120.21.786.786" @default.
• W768123309 hasPublicationYear "2012" @default.
• W768123309 type Work @default.
• W768123309 sameAs 768123309 @default.
• W768123309 citedByCount "1" @default.
• W768123309 countsByYear W7681233092014 @default.
• W768123309 crossrefType "journal-article" @default.
• W768123309 hasAuthorship W768123309A5006407427 @default.
• W768123309 hasAuthorship W768123309A5015273169 @default.
• W768123309 hasAuthorship W768123309A5020375942 @default.
• W768123309 hasAuthorship W768123309A5023951641 @default.
• W768123309 hasAuthorship W768123309A5025165056 @default.
• W768123309 hasAuthorship W768123309A5037460404 @default.
• W768123309 hasAuthorship W768123309A5053972254 @default.
• W768123309 hasAuthorship W768123309A5077872272 @default.
• W768123309 hasAuthorship W768123309A5078221812 @default.
• W768123309 hasAuthorship W768123309A5086016311 @default.
• W768123309 hasAuthorship W768123309A5086644018 @default.
• W768123309 hasAuthorship W768123309A5089694123 @default.
• W768123309 hasAuthorship W768123309A5091612811 @default.
• W768123309 hasConcept C104317684 @default.
• W768123309 hasConcept C11960822 @default.
• W768123309 hasConcept C185592680 @default.
• W768123309 hasConcept C2778729363 @default.
• W768123309 hasConcept C2910954276 @default.
• W768123309 hasConcept C34905852 @default.
• W768123309 hasConcept C46111723 @default.
• W768123309 hasConcept C501734568 @default.
• W768123309 hasConcept C502942594 @default.
• W768123309 hasConcept C55493867 @default.
• W768123309 hasConcept C62478195 @default.
• W768123309 hasConcept C6675166 @default.
• W768123309 hasConcept C70721500 @default.
• W768123309 hasConcept C86803240 @default.
• W768123309 hasConcept C87325107 @default.
• W768123309 hasConcept C97029542 @default.
• W768123309 hasConceptScore W768123309C104317684 @default.
• W768123309 hasConceptScore W768123309C11960822 @default.
• W768123309 hasConceptScore W768123309C185592680 @default.
• W768123309 hasConceptScore W768123309C2778729363 @default.
• W768123309 hasConceptScore W768123309C2910954276 @default.
• W768123309 hasConceptScore W768123309C34905852 @default.
• W768123309 hasConceptScore W768123309C46111723 @default.
• W768123309 hasConceptScore W768123309C501734568 @default.
• W768123309 hasConceptScore W768123309C502942594 @default.
• W768123309 hasConceptScore W768123309C55493867 @default.
• W768123309 hasConceptScore W768123309C62478195 @default.
• W768123309 hasConceptScore W768123309C6675166 @default.
• W768123309 hasConceptScore W768123309C70721500 @default.
• W768123309 hasConceptScore W768123309C86803240 @default.
• W768123309 hasConceptScore W768123309C87325107 @default.
• W768123309 hasConceptScore W768123309C97029542 @default.
• W768123309 hasLocation W7681233091 @default.
• W768123309 hasOpenAccess W768123309 @default.
• W768123309 hasPrimaryLocation W7681233091 @default.
• W768123309 hasRelatedWork W1173281462 @default.
• W768123309 hasRelatedWork W2030155066 @default.
• W768123309 hasRelatedWork W2031608873 @default.
• W768123309 hasRelatedWork W2123307509 @default.
• W768123309 hasRelatedWork W2284561540 @default.
• W768123309 hasRelatedWork W2293361133 @default.
• W768123309 hasRelatedWork W2328967005 @default.
• W768123309 hasRelatedWork W2507424916 @default.
• W768123309 hasRelatedWork W2777794149 @default.
• W768123309 hasRelatedWork W2782478947 @default.
• W768123309 hasRelatedWork W2902757402 @default.
• W768123309 hasRelatedWork W2953867576 @default.
• W768123309 hasRelatedWork W2960116156 @default.
• W768123309 hasRelatedWork W2970958214 @default.
• W768123309 hasRelatedWork W2979603825 @default.
• W768123309 hasRelatedWork W3097319035 @default.
• W768123309 hasRelatedWork W3120132520 @default.
• W768123309 hasRelatedWork W3166535759 @default.
• W768123309 hasRelatedWork W3172071219 @default.
• W768123309 hasRelatedWork W2009613406 @default.
• W768123309 isParatext "false" @default.
• W768123309 isRetracted "false" @default.
• W768123309 magId "768123309" @default.
• W768123309 workType "article" @default.